Glycemic Variability of Combination Therapies in T2DM
Recruiting · NCT07442006 · Interventional (participants receive a specific treatment) · Lead sponsor: JW Pharmaceutical
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Glycemic Variability of Combination Therapies in T2DM
Who can take part
Age range
19 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor.
Exclusion criteria
- History of acute or chronic metabolic acidosis
- Moderate to severe renal impairment (eGFR \< 45 mL/min/1.73m²)
- Severe hepatic impairment
- History of heart failure (NYHA Class III/IV)
Where it is running
1 location listed.
- The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator - Seoul, South Korea